US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Profusa Inc

0.0548

-0.0313-36.35%

Post-market: 0.05500.0002+0.36%19:59 EST

Volume:15.12M

Turnover:916.66K

Market Cap:4.74M

PE:-0.01

High:0.0649

Open:0.0600

Low:0.0523

Close:0.0861

52wk High:12.76

52wk Low:0.0523

Shares:86.41M

Float Shares:77.31M

Volume Ratio:2.87

T/O Rate:19.56%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.7155

EPS(LYR):-1.6468

ROE:--

ROA:-465.14%

PB:-0.14

PE(LYR):-0.03

Loading ...

Overview Company News Filings

Profusa Enacts 1-for-75 Reverse Stock Split

Profusa Inc. Held Special Shareholder Meeting

Profusa Reports Positive US Clinical Trial Results for Lumee Sensor in PAD Patients

NASD Most Active Issues

Profusa Stock Spikes As Lumee System Targets Research Market

Benzinga_recent_news

Profusa Inc. Partners with Leading Greek Vascular Surgeon Dr. Theodosios Bisdas

Profusa Inc - Announces Distributor Partnership in France With Medsell

THOMSON REUTERS

Profusa Secures French Distribution Deal for Lumee Oxygen Monitoring with MedSell

Profusa Inc. Announces Private Placement of Up to $5 Million in Unregistered Shares

Profusa Inc - Restructures Senior Secured Convertible Note

THOMSON REUTERS

Profusa Inc - Conversion Floor Price Increased to $0.35

THOMSON REUTERS

Profusa Raises Convertible Note Floor Price and Eliminates Mandatory Amortization Payments

Profusa Inc. Announces $100 Million Private Placement of Common Stock

Profusa Inc. Announces Date for Upcoming Special Stockholders Meeting

BRIEF-Profusa U.S. Study Met Primary End Points As Presented At Late Breaking Clinical Trials At Paris Vascular Insights 2025

Profusa Reports Positive Pilot Data for Lumee Oxygen Monitoring in PAD Patients

Profusa Announces US Clinical Study Results for Lumee Tissue Oxygen Monitoring at LINC 2026

Profusa Announces U.S. Clinical Trial Update for Lumee Oxygen Monitoring Platform at Paris Vascular Insights 2025

Profusa Inc - Targets $200-$250 Mln Revenue by 2030

THOMSON REUTERS

Profusa Targets Up to $13 Million Revenue in 2027 and $250 Million by 2030

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PFSA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PFSA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFSA\",,,,,undefined,":{"symbol":"PFSA","market":"US","secType":"STK","nameCN":"Profusa Inc","latestPrice":0.0548,"timestamp":1770325200000,"preClose":0.0861,"halted":0,"volume":15121269,"hourTrading":{"tag":"盘后","latestPrice":0.055,"preClose":0.0548,"latestTime":"19:59 EST","volume":679126,"amount":36353.468,"timestamp":1770339577637,"change":0.0002,"changeRate":0.00365,"amplitude":0.05292},"delay":0,"changeRate":-0.36353077816492446,"floatShares":77310100,"shares":86414295,"eps":-3.7155,"marketStatus":"Closed","change":-0.0313,"latestTime":"02-05 16:00:00 EST","open":0.06,"high":0.0649,"low":0.0523,"amount":916664.4822840301,"amplitude":0.146341,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3.7155,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770368400000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":0.0861,"preHourTrading":{"tag":"盘前","latestPrice":0.0599,"preClose":0.0861,"latestTime":"09:29 EST","volume":2514148,"amount":165325.19333512,"timestamp":1770301775329,"change":-0.0262,"changeRate":-0.304297,"amplitude":0.362369},"postHourTrading":{"tag":"盘后","latestPrice":0.055,"preClose":0.0548,"latestTime":"19:59 EST","volume":679126,"amount":36353.468,"timestamp":1770339577637,"change":0.0002,"changeRate":0.00365,"amplitude":0.05292},"volumeRatio":2.86774},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFSA\",,,,,undefined,":{"symbol":"PFSA","floatShares":77310100,"roa":"-465.14%","roe":"--","lyrEps":-1.646846,"volumeRatio":2.86774,"shares":86414295,"dividePrice":0,"high":0.0649,"amplitude":0.146341,"preClose":0.0861,"low":0.0523,"week52Low":0.0523,"pbRate":"-0.14","week52High":12.76,"institutionHeld":0,"latestPrice":0.0548,"eps":-3.7155,"divideRate":0,"volume":15121269,"delay":0,"ttmEps":-3.7155,"open":0.06,"prevYearClose":0.1048,"prevWeekClose":0.0927,"prevMonthClose":0.0927,"prevQuarterClose":0.1048,"fiveDayClose":0.0928,"twentyDayClose":0.0979,"sixtyDayClose":0.1819},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PFSA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-19","symbol":"PFSA","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763528400000,"reportTimeType":"post","actualEps":-0.7},{"market":"US","date":"2025-08-14","symbol":"PFSA","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-1.53},{"market":"US","date":"2025-07-14","symbol":"PFSA","reason":null,"defaultRemindTime":1752499800000,"announcedDate":"2025-07-11","type":"delisting","dateTimestamp":1752465600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PFSA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PFSA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PFSA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PFSA","date":"2026-02-04","current":-0.014749,"percent":0.834532,"low":-6.696361,"twenty":-1.575461,"median":-1.023963,"eighty":-0.277201,"high":-0.152027,"avg":-1.075606,"sd":0.927152,"marketCap":7906908},"quantilePoints":[{"date":"2025-07-18","current":-3.831423,"twenty":-4.218017,"median":-4.073044,"eighty":-3.928071,"marketCap":36632233},{"date":"2025-07-25","current":-2.461085,"twenty":-3.824519,"median":-3.13935,"eighty":-2.657558,"marketCap":23530434},{"date":"2025-08-01","current":-2.416213,"twenty":-3.824519,"median":-2.892379,"eighty":-2.465917,"marketCap":23101408},{"date":"2025-08-08","current":-1.622314,"twenty":-3.665394,"median":-2.485247,"eighty":-2.03093,"marketCap":15510945},{"date":"2025-08-15","current":-1.874291,"twenty":-3.116154,"median":-2.382041,"eighty":-1.7463,"marketCap":17920092},{"date":"2025-08-22","current":-1.5672,"twenty":-2.970975,"median":-2.025131,"eighty":-1.723933,"marketCap":15378937},{"date":"2025-08-29","current":-1.37063,"twenty":-2.735429,"median":-1.883856,"eighty":-1.643688,"marketCap":13449997},{"date":"2025-09-05","current":-1.104323,"twenty":-2.631601,"median":-1.785563,"eighty":-1.5672,"marketCap":10836723},{"date":"2025-09-12","current":-1.54104,"twenty":-2.485247,"median":-1.725866,"eighty":-1.369962,"marketCap":15122230},{"date":"2025-09-19","current":-1.136066,"twenty":-2.461085,"median":-1.689106,"eighty":-1.253014,"marketCap":11148218},{"date":"2025-09-26","current":-1.008092,"twenty":-2.416213,"median":-1.636938,"eighty":-1.112008,"marketCap":9892404},{"date":"2025-10-03","current":-1.089955,"twenty":-2.347868,"median":-1.587854,"eighty":-1.089955,"marketCap":10695731},{"date":"2025-10-10","current":-1.130386,"twenty":-2.054126,"median":-1.437792,"eighty":-1.090289,"marketCap":11092477},{"date":"2025-10-17","current":-1.275947,"twenty":-2.025131,"median":-1.368291,"eighty":-1.098977,"marketCap":12584666},{"date":"2025-10-24","current":-1.130953,"twenty":-1.93297,"median":-1.33353,"eighty":-1.104323,"marketCap":11154590},{"date":"2025-10-31","current":-1.068813,"twenty":-1.89342,"median":-1.297252,"eighty":-1.104323,"marketCap":10541701},{"date":"2025-11-07","current":-0.776339,"twenty":-1.874291,"median":-1.273461,"eighty":-1.077592,"marketCap":7657034},{"date":"2025-11-14","current":-0.807824,"twenty":-1.828037,"median":-1.261487,"eighty":-1.030479,"marketCap":7967564},{"date":"2025-11-21","current":-0.562991,"twenty":-1.74309,"median":-1.23162,"eighty":-0.992053,"marketCap":5552779},{"date":"2025-11-28","current":-0.37684,"twenty":-1.742283,"median":-1.201379,"eighty":-0.946945,"marketCap":11119786},{"date":"2025-12-05","current":-0.403995,"twenty":-1.729109,"median":-1.192595,"eighty":-0.807161,"marketCap":11921093},{"date":"2025-12-12","current":-0.391753,"twenty":-1.723933,"median":-1.159952,"eighty":-0.778328,"marketCap":11559848},{"date":"2025-12-19","current":-0.250633,"twenty":-1.697769,"median":-1.13351,"eighty":-0.74063,"marketCap":7395675},{"date":"2025-12-26","current":-0.177179,"twenty":-1.688657,"median":-1.125039,"eighty":-0.51444,"marketCap":5228204},{"date":"2026-01-02","current":-0.233271,"twenty":-1.680392,"median":-1.109335,"eighty":-0.406755,"marketCap":6883364},{"date":"2026-01-09","current":-0.218135,"twenty":-1.657187,"median":-1.098977,"eighty":-0.389527,"marketCap":6436733},{"date":"2026-01-16","current":-0.219248,"twenty":-1.631088,"median":-1.083773,"eighty":-0.34541,"marketCap":6469574},{"date":"2026-01-23","current":-0.337949,"twenty":-1.619553,"median":-1.061173,"eighty":-0.336075,"marketCap":9972209},{"date":"2026-01-30","current":-0.271765,"twenty":-1.600246,"median":-1.030479,"eighty":-0.288458,"marketCap":8019246},{"date":"2026-02-04","current":-0.267958,"twenty":-1.575461,"median":-1.023963,"eighty":-0.277201,"marketCap":7906908}],"updateTime":1770336535253},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PFSA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609308831","title":"Profusa Enacts 1-for-75 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2609308831","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609308831?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:00","pubTimestamp":1770296411,"startTime":"0","endTime":"0","summary":"Profusa Inc. has announced a 1-for-75 reverse stock split of its common stock, effective February 9, 2026. Following the split, the number of outstanding shares will decrease from approximately 92.4 million to about 1.2 million, while the number of authorized shares remains unchanged. The company will continue trading under the ticker symbol \"PFSA\" with a new CUSIP number.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Profusa Inc. published the original content used to generate this news brief via GlobeNewswire  on February 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL71JCmd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BKPKM429.USD","NDAQ","BK4585","LU2210150020.SGD","SG9999014013.SGD","BK4588","SG9999014021.USD","SG9999014005.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","LU0314104364.USD","BK4082","PFSA","BK4112"],"gpt_icon":0},{"id":"2608531818","title":"Profusa Inc. Held Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2608531818","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608531818?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:31","pubTimestamp":1770067874,"startTime":"0","endTime":"0","summary":"Profusa Inc. held a Special Meeting of Stockholders on January 27, 2026. Stockholders approved an amendment to the Certificate of Incorporation to allow the Board of Directors to effect one or more reverse stock splits of the company's common stock at a ratio between 1-for-30 and 1-for-200, to be determined at the Board's discretion prior to January 27, 2028. The appointment of CBIZ CPAs P.C. as the company's independent registered public accounting firm for the year ending December 31, 2025, was ratified. Authorization was also given for potential adjournment of the Special Meeting to a later date if necessary.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Profusa Inc. published the original content used to generate this news brief v","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL3Rm0GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","PFSA"],"gpt_icon":0},{"id":"2607087671","title":"Profusa Reports Positive US Clinical Trial Results for Lumee Sensor in PAD Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2607087671","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607087671?lang=en_us&edition=fundamental","pubTime":"2026-01-29 21:00","pubTimestamp":1769691634,"startTime":"0","endTime":"0","summary":"Profusa Inc. has announced positive results from a US-based clinical study evaluating the Lumee sensor in patients with peripheral artery disease . The results, which were presented at the Leipzig Interventional Course  2026, showed that the sensors remained functional for up to one year and no sensor placement related adverse events were reported. The company expects to begin commercial activities in the European Union with Lumee oxygen revenue projected to commence in the second quarter of 2026, and estimates potential revenue of $0.5 to $2 million in 2026 and $9 to $13 million in 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Profusa Inc. published the original content used to generate this news brief via GlobeNewswire  on Jan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL4NvGcS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4112","IE00BGHQF748.EUR","NDAQ","BK4585","LU2210150020.SGD","PFSA","BK4588","SG9999014005.SGD","SG9999014039.USD","BK4082","LU2210149790.SGD","LU0314104364.USD","SG9999014021.USD","IE00B3QW5Z07.USD","LU2095319765.USD"],"gpt_icon":0},{"id":"2605142979","title":"NASD Most Active Issues","url":"https://stock-news.laohu8.com/highlight/detail?id=2605142979","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605142979?lang=en_us&edition=fundamental","pubTime":"2026-01-21 06:30","pubTimestamp":1768948200,"startTime":"0","endTime":"0","summary":"Super Micro Computer        SMCI    78,722,526     32.64     3.22     10.94. ProShares UltraPro QQQ      TQQQ    75,495,869     54.14    -0.24     -0.44. Strive Cl A                 ASST    61,986,970    0.9481    -0.02     -2.31. Direxion Dly TSLA Br 1X     TSLS    61,877,283      5.22     0.02      0.38. Invesco QQQ Trust I          QQQ    60,634,088    621.26    -0.52     -0.08. Direxion TSLA Bull 2X       TSLL    54,277,422     17.91    -0.07     -0.39","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999006266.SGD","LU0323591593.USD","LU0081259029.USD","LU0708995401.HKD","SG9999015945.SGD","LU1066053197.SGD","SG9999015986.USD","LU1629891620.HKD","LU0792757196.USD","LU0097036916.USD","LU2362541273.HKD","BK4023","IE0002270589.USD","IE00B894F039.SGD","LU1720051017.SGD","LU0203345920.USD","LU0823414478.USD","BK4534","LU2362541513.USD","PFSA","BK4515","IE00B19Z8W00.USD","BK4529","IE00BJLML261.HKD","LU1323610961.USD","TSLQ","LU0053671581.USD","BK4532","TSLI","TSLR","LU1316542783.SGD","TSLW","BK4512","LU0689472784.USD","LU0157215616.USD","LU0823411888.USD","LU0056508442.USD","LU0234572021.USD","SG9999002604.SGD","IE00B1BXHZ80.USD","TSLG","BK4511","LU1066051225.USD","LU0109391861.USD","LU0943347566.SGD","LU2063271972.USD","BK4099","LU2048586759.USD","BK4605","BK4561","LU0466842654.USD","LU2756315664.SGD","LU0348723411.USD","IE00BK4W5M84.HKD","TSLP","LU0210637038.USD","TSLS","CRSH","LU1066051811.HKD","LU2420271590.USD","LU1435385759.SGD","LU2089985449.USD","SG9999002620.SGD","BK4547","BK4585","LU1839390173.USD","BK4527","BK4566","LU2750360997.AUD","LU1852331112.SGD","IE00BSNM7G36.USD","LU1267930813.SGD","LU2471134879.HKD","LU2471134952.CNY","LU0889565833.HKD","LU0820561909.HKD","LU0532188223.SGD","NVDA","BK4516","LU1066051498.USD","LU2471134796.USD","LU0642271901.SGD","LU1242518857.USD","LU0345769128.USD","LU2286300806.USD","LU1551013425.SGD","IBRX","LU0441851309.USD","LU1861220033.SGD","LU1861215975.USD","TSLL","LU2756315318.SGD","LU0077335932.USD","LU2023250330.USD","LU2250418816.HKD","IE00BZ9MQY76.HKD","LU1242518931.SGD","LU2896262040.SGD","BK4574","BK4551","LU2213496289.HKD","MULL","SG9999002406.SGD","SG9999002679.SGD","LU2326559502.SGD","LU0321505439.SGD",".IXIC","LU1861558580.USD","BK4548","BK4550","LU0053666078.USD","LU1232071149.USD","LU1778281490.HKD","LU0321505868.SGD","IE00B1XK9C88.USD","LU2543165471.USD","SG9999015952.SGD","LU0672654240.SGD","IE00BK4W5L77.USD","LU0719512351.SGD","LU0889566641.SGD","TSL","BK4543","LU0210536198.USD","BK4604","LU1674673691.USD","BK4553","LU0345770308.USD","LU2108987350.USD","IE00B19Z9Z06.USD","LU0345769631.USD","LU0964807845.USD","SG9999015978.USD","LU1429558221.USD","TSYY","BK4141","LU1674673428.USD","LU2236285917.USD","LU0109392836.USD","BK4170","BK4533","LU2456880835.USD","BK4613","IE0034235303.USD","SG9999013486.USD","IE00B19Z3B42.SGD","LU1803068979.SGD","BK4588","LU0979878070.USD","TSLY","BK4535","MUD","BK4602","IE00B19Z9P08.USD","LU0127658192.USD","SG9999013478.USD","IE00B19Z8X17.USD","LU2360107168.USD","IE00BWXC8680.SGD","LU0274383776.USD","LU2148611432.USD","SG9999013460.SGD","LU2211815571.USD","LU1548497426.USD","BK4593","LU2357305700.SGD","LU2458330169.SGD","LU1267930730.SGD","SGXZ58947870.SGD","BK4581","LU1145028129.USD","SG9999001135.SGD","TSLT","BK4230","BK4555","LU2362540622.SGD","BK4554","LU2360106780.USD","BK4598","LU0316494557.USD","LU0820562030.AUD","LU2125910500.SGD","TSDD","TQQQ","AZN","SG9999002414.USD","LU0082616367.USD","BK4575","BK4592","LU0820561818.USD","LU2462157665.USD","LU1366333091.USD","BK4579","LU1914381329.SGD","IE00B19Z9505.USD","LU1839511570.USD","LU2750360641.GBP","LU2087621335.USD","LU2290526834.HKD","WMT","04335","LU0320765059.SGD","LU1720051108.HKD","LU0198837287.USD","LU0203347892.USD","TESL","LU2602419157.SGD","IE00B7SZLL34.SGD","LU1366192091.USD","LU0234570918.USD","LU2931357623.SGD","LU2471134523.USD","GB00BDT5M118.USD","LU1861559042.SGD","LU0345770993.USD","LU2458330243.SGD","BK4022","LU1551013342.USD","TSLZ","BK4122","IE00B19Z3581.USD","LU2045819591.USD","LU2403377893.USD","LU2249611893.SGD","LU2417539215.USD","BK4612"],"gpt_icon":1},{"id":"2604491330","title":"Profusa Stock Spikes As Lumee System Targets Research Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2604491330","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604491330?lang=en_us&edition=fundamental","pubTime":"2026-01-17 01:51","pubTimestamp":1768585860,"startTime":"0","endTime":"0","summary":"Profusa shares surged on heavy volume after launching its Lumee tissue oxygen monitoring system for research use, targeting contract research organizations and near-term service revenue.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/16/Medical-Professionals-In-Research-And-De.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/16/Medical-Professionals-In-Research-And-De.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/01/49973068/profusa-stock-spikes-as-lumee-system-targets-research-market","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/01/49973068/profusa-stock-spikes-as-lumee-system-targets-research-market","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["SMA","PFSA","BK4217","BK4082"],"gpt_icon":0},{"id":"2601369705","title":"Profusa Inc. Partners with Leading Greek Vascular Surgeon Dr. Theodosios Bisdas","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369705","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369705?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:30","pubTimestamp":1767875420,"startTime":"0","endTime":"0","summary":"Profusa Inc. has announced the addition of Dr. Theodosios Bisdas, a renowned vascular surgeon and Head of the Clinic of Vascular Surgery at the Athens Medical Center in Greece, to its customer base. The collaboration will see Dr. Bisdas integrating Profusa’s Lumee Oxygen tissue monitoring system into his practice. Profusa expressed enthusiasm for working with Dr. Bisdas and exploring further clinical partnerships as the company continues to evaluate additional vascular applications for its platform technology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Profusa Inc. published the original content used to generate this news brief via GlobeNewswire  on January 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL1bkttB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014013.SGD","LU2210149790.SGD","SG9999014021.USD","BK4585","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014039.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4082","BK4112","NDAQ","PFSA","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014005.SGD"],"gpt_icon":0},{"id":"2595779417","title":"Profusa Inc - Announces Distributor Partnership in France With Medsell","url":"https://stock-news.laohu8.com/highlight/detail?id=2595779417","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595779417?lang=en_us&edition=fundamental","pubTime":"2025-12-31 20:30","pubTimestamp":1767184239,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nFWN3Y00M7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","PFSA"],"gpt_icon":0},{"id":"2595441779","title":"Profusa Secures French Distribution Deal for Lumee Oxygen Monitoring with MedSell","url":"https://stock-news.laohu8.com/highlight/detail?id=2595441779","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595441779?lang=en_us&edition=fundamental","pubTime":"2025-12-31 20:30","pubTimestamp":1767184217,"startTime":"0","endTime":"0","summary":"Profusa Inc. announced a new distributor partnership with MedSell to commercialize its Lumee Oxygen tissue monitoring technology in France. MedSell will distribute the product in both hospital settings and outpatient care, particularly for wound care and healing clinics treating patients with complex and chronic wounds. This agreement expands Profusa’s European commercial network, which already includes distributor partnerships in Spain, Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia. Additionally, Profusa’s collaboration with Professor Yann Gouffic of Groupe Hospitalier Paris Saint Joseph continues, with the adoption of Lumee Oxygen monitoring technology in clinical practice and studies. Profusa aims to begin commercialization in Europe in the second quarter of 2026, targeting potential revenues of $0.5 to $2 million in 2026 and $9 to $13 million in 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL8CyHL9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","SG9999014039.USD","BK4112","LU2095319765.USD","BK4082","IE00B3QW5Z07.USD","NDAQ","PFSA","BK4585","IE00BGHQF748.EUR","SG9999014021.USD","BK4588","IE00B64PRP62.GBP","LU0314104364.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2595792584","title":"Profusa Inc. Announces Private Placement of Up to $5 Million in Unregistered Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2595792584","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595792584?lang=en_us&edition=fundamental","pubTime":"2025-12-30 20:31","pubTimestamp":1767097903,"startTime":"0","endTime":"0","summary":"Profusa Inc. has announced an amendment to its Securities Purchase Agreement, allowing for the private placement of up to 13,650,000 shares of common stock at prices between $0.111 and $0.14 per share during a specified modification period ahead of an anticipated reverse stock split. Additionally, under the revised agreement, purchasers are obligated to buy additional notes with an aggregate principal amount of up to $5,555,556 for a purchase price of up to $5,000,000, contingent on certain conditions being met, including the reduction of outstanding balances from earlier tranches and the effectiveness of a registration statement covering the conversion shares. The amendments also adjust mandatory prepayment terms related to proceeds from equity offerings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nNDL5TJ7YZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFSA","BK4082"],"gpt_icon":0},{"id":"2595925587","title":"Profusa Inc - Restructures Senior Secured Convertible Note","url":"https://stock-news.laohu8.com/highlight/detail?id=2595925587","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595925587?lang=en_us&edition=fundamental","pubTime":"2025-12-30 20:30","pubTimestamp":1767097827,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nFWN3Y00F0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PFSA","BK4082"],"gpt_icon":0},{"id":"2595792559","title":"Profusa Inc - Conversion Floor Price Increased to $0.35","url":"https://stock-news.laohu8.com/highlight/detail?id=2595792559","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595792559?lang=en_us&edition=fundamental","pubTime":"2025-12-30 20:30","pubTimestamp":1767097827,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nFWN3Y00F0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","PFSA"],"gpt_icon":0},{"id":"2595305792","title":"Profusa Raises Convertible Note Floor Price and Eliminates Mandatory Amortization Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2595305792","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595305792?lang=en_us&edition=fundamental","pubTime":"2025-12-30 20:30","pubTimestamp":1767097819,"startTime":"0","endTime":"0","summary":"Profusa Inc. announced it has restructured its Senior Secured Convertible Notes, increasing the conversion floor price to $0.35 and eliminating mandatory amortization payments for greater repayment flexibility and reduced dilution. The company also adjusted its equity line of credit payment requirements, aiming to strengthen its balance sheet and focus resources on growth initiatives and inventory build in early 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Profusa Inc. published the original content used to generate this news brief via GlobeNewswire  on December 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nNDL8vYP3g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4082","LU0314104364.USD","LU2210149790.SGD","IE00B64PRP62.GBP","SG9999014005.SGD","SG9999014021.USD","SG9999014013.SGD","BK4585","SG9999014039.USD","PFSA","LU2210150020.SGD","NDAQ","IE00B3QW5Z07.USD","BK4588","LU2095319765.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2593494856","title":"Profusa Inc. Announces $100 Million Private Placement of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2593494856","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593494856?lang=en_us&edition=fundamental","pubTime":"2025-12-23 19:06","pubTimestamp":1766487990,"startTime":"0","endTime":"0","summary":"Profusa Inc. has amended its Securities Purchase Agreement with Ascent Partners Fund LLC, allowing the company to issue and sell up to $100 million of its common stock in a private placement. Under the amended terms, during a specified modification period, shares may be issued at a floor price of $0.111 per share for up to 13,650,000 shares, after which the floor price will revert to $0.14 per share. The agreement is subject to certain conditions and limitations, and the lower floor price applies only until a reverse stock split, expected to be presented to shareholders in January 2026, becomes effective.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Profusa Inc. published the original content used to generate this news brief via EDGA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL9xwH7t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFSA","BK4082"],"gpt_icon":0},{"id":"2593481826","title":"Profusa Inc. Announces Date for Upcoming Special Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2593481826","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593481826?lang=en_us&edition=fundamental","pubTime":"2025-12-22 19:05","pubTimestamp":1766401556,"startTime":"0","endTime":"0","summary":"Profusa Inc. has announced that it will hold a special meeting of stockholders virtually via teleconference on [●], 2026. The meeting has been called to address matters described in the meeting materials provided to stockholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Profusa Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL4RPjBL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFSA","BK4082"],"gpt_icon":0},{"id":"2591469516","title":"BRIEF-Profusa U.S. Study Met Primary End Points As Presented At Late Breaking Clinical Trials At Paris Vascular Insights 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2591469516","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591469516?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:33","pubTimestamp":1765801994,"startTime":"0","endTime":"0","summary":"BRIEF-Profusa U.S. Study Met Primary End Points As Presented At Late Breaking Clinical Trials At Paris Vascular Insights 2025Dec 15 (Reuters) - Profusa Inc PFSA.O:PROFUSA U.S. STUDY MET PRIMARY END PO","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA4CB8CT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFSA","BK4082"],"gpt_icon":0},{"id":"2591646669","title":"Profusa Reports Positive Pilot Data for Lumee Oxygen Monitoring in PAD Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2591646669","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591646669?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:30","pubTimestamp":1765801811,"startTime":"0","endTime":"0","summary":"Profusa Inc., a commercial stage digital health company, announced pilot phase data from a clinical study demonstrating that its Lumee oxygen tissue monitoring technology met the study's primary endpoints. The results were presented at the late breaking clinical trial session at the Paris Vascular Insights  2025 on December 13, 2025, in Paris, France. The study, conducted in the U.S., showed that Lumee oxygen tissue monitoring is a safe and effective method for long-term monitoring of peripheral artery disease  patients, with sensors remaining functional for up to one year and no sensor placement related adverse events reported. Profusa plans to begin commercialization of Lumee tissue oxygen monitoring in the European Union at the beginning of the second quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational pur","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL1hFhRL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014005.SGD","LU0314104364.USD","NDAQ","SG9999014021.USD","PFSA","IE00BGHQF748.EUR","BK4588","SG9999014013.SGD","LU2210150020.SGD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4112","BK4585","LU2095319765.USD","SG9999014039.USD","BK4082"],"gpt_icon":0},{"id":"2590874519","title":"Profusa Announces US Clinical Study Results for Lumee Tissue Oxygen Monitoring at LINC 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590874519","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590874519?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:30","pubTimestamp":1765459837,"startTime":"0","endTime":"0","summary":"Profusa Inc., a commercial-stage digital health company, has announced the acceptance of their abstract for presentation at the Leipzig Interventional Course  2026, which will take place from January 27-30, 2026, in Leipzig, Germany. The presentation is scheduled for January 28, 2026, and will provide additional insights from a US-based pilot clinical study evaluating the Lumee tissue oxygen monitoring technology in patients with peripheral artery disease . The company states that the Lumee technology enables continuous, real-time measurement of tissue oxygen directly within the body, with intended use in both clinical and home settings. The results from this study will be presented at the upcoming conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL8vrmZD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014013.SGD","LU0314104364.USD","BK4588","NDAQ","LU2095319765.USD","IE00BKPKM429.USD","PFSA","SG9999014021.USD","BK4082","BK4585","SG9999014039.USD","SG9999014005.SGD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2585462752","title":"Profusa Announces U.S. Clinical Trial Update for Lumee Oxygen Monitoring Platform at Paris Vascular Insights 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462752","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585462752?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:15","pubTimestamp":1763990108,"startTime":"0","endTime":"0","summary":"Profusa Inc. has announced the acceptance of an abstract for a Late Breaking Clinical Trial Update presentation at the upcoming Paris Vascular Insights  2025, to be held on December 11-13, 2025, in Paris, France. The study evaluates the Lumee Oxygen tissue monitoring platform, which uses an implantable hydrogel sensor to monitor tissue oxygen dynamics in patients with peripheral arterial disease . The results of the U.S.-based clinical study will be presented at the conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Profusa Inc. published the original content used to generate this news brief via GlobeNewswire  on November 24, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL6SwL5N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","NDAQ","BK4585","BK4082","PFSA","LU2210149790.SGD","BK4112","BK4588"],"gpt_icon":0},{"id":"2584997114","title":"Profusa Inc - Targets $200-$250 Mln Revenue by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2584997114","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584997114?lang=en_us&edition=fundamental","pubTime":"2025-11-20 06:46","pubTimestamp":1763592361,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nFWN3WV12L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","PFSA"],"gpt_icon":0},{"id":"2584971129","title":"Profusa Targets Up to $13 Million Revenue in 2027 and $250 Million by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2584971129","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584971129?lang=en_us&edition=fundamental","pubTime":"2025-11-20 06:45","pubTimestamp":1763592307,"startTime":"0","endTime":"0","summary":"Profusa Inc. has outlined its financial outlook, projecting potential revenue of $0.5 to $2 million in 2026 and $9 to $13 million in 2027, with a longer-term target of $200 to $250 million in revenue by 2030. The company reported a significant reduction in net debt, from $34 million to $14 million as of October 31, 2025, and completed a manufacturing build-out ahead of anticipated product shipments and revenue generation in early 2026. Profusa's operational progress and expanded sales footprint in Europe support its revenue growth plans for the coming years.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Profusa Inc. published the original content used to generate this news brief via GlobeNewswire  on November 19, 2025, and is solely r","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL3XTTg5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BKPKM429.USD","LU2210149790.SGD","IE00BGHQF748.EUR","LU2095319765.USD","NDAQ","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","PFSA","LU2210150020.SGD","BK4112","BK4588","BK4082"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":44,"code":"91000000","status":"200"}]}}